Boston Scientific has not actively responded to the approach, according to the report, which came from sources “familiar with the matter,” according to the WSJ.
“As a matter of company policy, we do not comment on potential M&A,” a Stryker representative said, according to a Reuters report.
The deal would create a combined medical device company worth more than $110 billion, according to Reuters, with Boston Scientific holding a market value of approximately $44 billion while Stryker commands a value of nearly $67 billion.
If a deal between the two major players took place, it would likely be the largest M&A deal in the medtech field so far this year.
Shares in Boston Scientific have risen 7.6% so far today, at $34.36, while shares in Stryker have fallen 1.9%, at $175.49 as of 11:37 a.m. EDT.
In late May, Boston Scientific and the U.S. Internal Revenue Service finalized their settlement of a tax beef dating back to the $26 billion acquisition of Guidant in 2006, which would see the company pay nearly $610 million in taxes and interest.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.